2102192-68-5
2102192-68-5 structure
- Name: Envafolimab
- Chemical Name: Envafolimab
- CAS Number: 2102192-68-5
- Molecular Formula:
- Molecular Weight:
- Catalog: Signaling Pathways Immunology/Inflammation PD-1/PD-L1
- Create Date: 2022-08-06 14:30:52
- Modify Date: 2024-01-11 12:06:01
-
Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- PD-L1 antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC50 value of 5.25 nm. Envafolimab shows antitumor activity. Envafolimab has the potential for the research of solid tumors[1][2][3].
| Name | Envafolimab |
|---|
| Description | Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- PD-L1 antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC50 value of 5.25 nm. Envafolimab shows antitumor activity. Envafolimab has the potential for the research of solid tumors[1][2][3]. |
|---|---|
| Related Catalog | |
| In Vitro | Envafolimab (0-2.51 nM) induces T-cell cytokine (IFN-γ) production in a dose- and time-dependent manner[3]. |
| In Vivo | Envafolimab (0.18-0.92 mg/kg; i.p.; four times over 2 weeks) shows antitumor activity with a half-life of ~72 h in NOD-SCID mice (A375 cells)[3]. |
| References |
| No Any Chemical & Physical Properties |